预约演示
更新于：2026-02-27
Benazepril Hydrochloride
盐酸贝那普利
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-06-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
关联
57
项与 盐酸贝那普利 相关的临床试验ChiCTR2500109077
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets and Sacubitril Alisartan Calcium Tablets Combined with Amlodipine Besylate Tablets
ChiCTR2500108026
Efficacy and safety of Ambrisentan on idiopathic membranous nephropathy----a prospective, multi-center, randomized and controlled study
ChiCTR2500106011
Clinical trial of the safety and efficacy of amlodipine Benazepril tablets (II) for antihypertensive treatment in patients with grade 2 hypertension who are not eligible for free association
100 项与 盐酸贝那普利 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝那普利 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝那普利 相关的专利（医药）
登录后查看更多信息
1,080
项与 盐酸贝那普利 相关的文献（医药）2026-02-01HYPERTENSION RESEARCH
Antihypertensive treatment effect of two dual therapies according to sodium sensitivity
Article
作者: Luo, Yihong ; Qiu, Yinglong ; Xu, Fei ; Luo, Yong ; Deng, Bing ; Chen, Jianhua ; He, Guibin ; Yu, Hong ; Lu, Yingmin ; Wang, Ji-Guang ; Qiu, Hailong ; Wang, Jiahong ; Li, Yan ; Wu, Qiong ; Zhang, Yanping ; Xiao, Jianqiang ; Wang, Mei-Ling ; Zhao, Kai ; Liu, Min ; Zhou, Zhihong ; Zhang, Di ; Peng, Qing ; Chen, Xin ; Huang, Qi-Fang ; Hu, Kun ; Wang, Leijun ; Wang, Ping
We investigated the blood pressure (BP) lowering efficacy of two dual antihypertensive therapies, the amlodipine/benazepril and benazepril/hydrochlorothiazide combinations, according to sodium sensitivity risk (SSR) as assessed by ambulatory BP monitoring (ABPM). In a multi-center, randomized, actively-controlled, parallel-group trial, patients with a clinic systolic/diastolic BP of 140 to 179/90 to 109 mmHg while on benazepril 10 mg daily monotherapy, received 24-week antihypertensive treatment with amlodipine/benazepril 5/10 mg (n = 213) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 212). SSR was assessed with two 24-h ABPM parameters, BP dipper status at night and 24-h mean heart rate. The amlodipine/benazepril combination, compared with benazepril/hydrochlorothiazide combination, showed greater BP lowering effect in 304 patients with low/intermediate SSR, but smaller BP lowering effect in 121 patients with high SSR, with significant (P ≤ 0.046) interaction for 24-h, daytime and morning systolic BP. Indeed, in comparison with the benazepril/hydrochlorothiazide group, 24-h and daytime systolic BP reductions in the amlodipine/benazepril group were 4.19 and 5.17 mmHg, respectively, greater in patients with low/intermediate SSR, while morning systolic BP reductions was 10.8 mmHg smaller in patients with high SSR. Similar trends were observed for the other systolic BP measurements and diastolic BP measurements, although statistical significance was not attained (P ≥ 0.069). Sensitivity analysis in 367 patients with sustained hypertension was confirmatory. In conclusion, the antihypertensive treatment effect of the amlodipine/benazepril and benazepril/hydrochlorothiazide combinations was dependent on SSR as assessed by ABPM, with the former combination being more efficacious in patients with low/intermediate SSR, but less efficacious in patients with high SSR.
2026-02-01BIOCHEMICAL GENETICS
Benazepril Promotes the Proliferation and Differentiation of Urine-Derived Stem Cells from Children with Nephrotic Syndrome During the Chronic Kidney Disease Stage
Article
作者: Liu, Ming ; Li, Cheng ; Yang, Yuan ; Xiong, Geng ; Guo, Ling ; Huang, Chengqiang
Nephrotic Syndrome (NS), especially in the Chronic Kidney Disease (CKD) stage, poses significant challenges in pediatric nephrology. Urine-derived stem cells (USCs) show promise for renal repair and regeneration. While benazepril is commonly used to treat CKD, its impact on USCs from children with NS during the CKD stage is unclear. USCs were isolated from the urine of 6 healthy children and 6 with NS (CKD stage), cultured through passages, and their morphology and cell surface markers were assessed microscopically and by flow cytometry, respectively. USCs were treated with benazepril at concentrations of 1, 10, 20, 40 μmol/L, and proliferation was evaluated using the CCK-8 assay. ROS levels were measured using DCFH-DA probe, and the expression levels of IL-1β, Connexin 43, AEC, ACE2, Ang2, AQP-1 and E-cadherin were analyzed by Western Blot. Tubular epithelial cell differentiation was also examined. USCs could be cultured from both healthy and NS (CKD stage) children, but USCs from NS children only reached passage 5 and exhibited weaker proliferation and differentiation abilities compared to those from healthy children. IL-1β, Connexin 43, ROS,ACE and Ang2 levels were higher in USCs from NS children than in those from healthy children, while ACE2 showed the opposite trend. Treatment with 1 μmol/L benazepril enhanced the proliferation and differentiation ability of USCs from NS children, inhibiting the level of inflammation factors, ROS, ACE and Ang2 while promoting ACE2 expression in these cells. This study offers valuable insights for future USCs applications.
2026-01-01RESEARCH IN VETERINARY SCIENCE
The cost divide: Why veterinary medicinal products for dogs and cats in the EU cost more than their human equivalents
Article
作者: Pellegrino, Alfonso ; Stasi, Alessandro
This paper provides a comprehensive analysis of the European Union (EU) pricing policies for veterinary medicinal products (VMPs), focusing on the comparative costs of human and pet veterinary formulations of common medications. It examines market dynamics, regulatory frameworks, and structural factors that influence price disparities, drawing on case studies from Italy, France, and Germany. The analysis highlights the role of Regulation (EU) 2019/6, the evolution of the EU VMP market, and the specific economic and regulatory conditions that allow for significant price differences despite identical active ingredients. Using comparative data on furosemide, amoxicillin, benazepril, and prednisone, the paper identifies how lack of public price negotiation, high VAT rates, concentrated market structure, and limitations in pet insurance coverage contribute to affordability challenges. The findings provide policy-relevant insights into how the EU could better align VMP pricing with principles of accessibility, sustainability, and innovation.
100 项与 盐酸贝那普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 中国 | 2000-12-31 | |
| 心脏衰竭 | 中国 | 1999-01-01 | |
| 高血压 | 美国 | 1991-06-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 200 | Control (anti-hypertensive agents except for RAS inhibitors) | 膚顧簾積鹽憲淵襯獵鑰(網顧齋蓋壓廠範願蓋憲) = 醖淵糧願艱積醖艱顧襯 簾艱鏇選築構獵獵簾夢 (鹽製鬱簾糧蓋觸憲憲網, 1.16 ~ 1.59) 更多 | 积极 | 2020-03-01 | |
膚顧簾積鹽憲淵襯獵鑰(網顧齋蓋壓廠範願蓋憲) = 鹽蓋衊艱積網糧壓積憲 簾艱鏇選築構獵獵簾夢 (鹽製鬱簾糧蓋觸憲憲網, 0.90 ~ 1.34) 更多 | |||||||
临床4期 | 291 | 築網蓋淵齋鑰構艱製範 = 鏇夢鑰夢廠艱鬱獵製鬱 選鹽積衊繭觸鏇壓願製 (網夢襯願蓋衊遞壓築窪, 齋襯鹹鏇繭網範範淵壓 ~ 構廠鑰顧鏇鏇鹹淵鑰獵) 更多 | - | 2017-12-11 | |||
(ACEI Continuation) | 築網蓋淵齋鑰構艱製範 = 範襯簾膚齋簾觸選觸網 選鹽積衊繭觸鏇壓願製 (網夢襯願蓋衊遞壓築窪, 壓窪鑰鹽鹹繭鹹鹽鹽簾 ~ 襯餘構簾廠鏇製顧糧糧) 更多 | ||||||
临床4期 | 30 | (Losartan) | 蓋積鬱膚鏇鑰壓願襯鹽(鹹築獵願夢憲簾窪鬱網) = 範襯構鹹鬱鏇網襯憲鏇 廠糧糧鏇鹽遞鑰構鏇觸 (衊製獵鬱窪簾觸觸鬱鏇, 膚壓衊鹹遞鑰簾獵糧窪 ~ 製艱齋網鏇衊範夢觸網) 更多 | - | 2015-11-11 | ||
(Benazepril) | 蓋積鬱膚鏇鑰壓願襯鹽(鹹築獵願夢憲簾窪鬱網) = 艱鑰鬱鹹網鏇鏇鹽選糧 廠糧糧鏇鹽遞鑰構鏇觸 (衊製獵鬱窪簾觸觸鬱鏇, 繭遞遞夢構選鏇觸顧醖 ~ 糧簾觸襯餘構蓋範獵顧) 更多 | ||||||
临床2期 | 6 | laboratory biomarker analysis+benazepril hydrochloride (Arm I) | 淵襯簾網蓋獵窪願餘鏇(襯艱餘衊憲積憲遞顧簾) = 艱簾獵觸鬱鏇壓選鹽醖 繭築艱顧鬱鹹鏇廠餘艱 (遞衊繭築鹽窪構憲鏇鹹, 0) 更多 | - | 2014-12-15 | ||
lisinopril+laboratory biomarker analysis (Arm II) | 淵襯簾網蓋獵窪願餘鏇(襯艱餘衊憲積憲遞顧簾) = 願鹽遞鬱選觸選範窪齋 繭築艱顧鬱鹹鏇廠餘艱 (遞衊繭築鹽窪構憲鏇鹹, 0) 更多 | ||||||
临床3期 | 184 | 夢觸觸選鑰膚鏇糧蓋顧(醖鏇憲範構鹹鏇憲獵鹽) = 壓願糧鹽餘壓淵衊繭網 築範夢積夢夢艱壓獵醖 (醖壓選鏇選餘製積蓋壓, 0.72) 更多 | - | 2014-10-01 | |||
N/A | 46 | (Low Dose Inhibition of RAS) | 憲襯衊積網鑰鑰製艱獵(選鹽壓築顧鏇壓選網鹽) = 鹹艱遞獵廠廠簾獵糧顧 夢膚築鑰簾鏇願鬱齋憲 (醖壓簾選衊襯蓋醖遞鏇, 652.3) 更多 | - | 2012-03-30 | ||
(Agressive Inhibition of the RAS) | 憲襯衊積網鑰鑰製艱獵(選鹽壓築顧鏇壓選網鹽) = 繭夢簾夢齋願範憲顧觸 夢膚築鑰簾鏇願鬱齋憲 (醖壓簾選衊襯蓋醖遞鏇, 404.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用